<code id='16A7D79284'></code><style id='16A7D79284'></style>
    • <acronym id='16A7D79284'></acronym>
      <center id='16A7D79284'><center id='16A7D79284'><tfoot id='16A7D79284'></tfoot></center><abbr id='16A7D79284'><dir id='16A7D79284'><tfoot id='16A7D79284'></tfoot><noframes id='16A7D79284'>

    • <optgroup id='16A7D79284'><strike id='16A7D79284'><sup id='16A7D79284'></sup></strike><code id='16A7D79284'></code></optgroup>
        1. <b id='16A7D79284'><label id='16A7D79284'><select id='16A7D79284'><dt id='16A7D79284'><span id='16A7D79284'></span></dt></select></label></b><u id='16A7D79284'></u>
          <i id='16A7D79284'><strike id='16A7D79284'><tt id='16A7D79284'><pre id='16A7D79284'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:15664
          Amgen HQ
          Mark J. Terrill/AP

          A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

          The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

          advertisement

          Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Color Health wants to make cancer screenings convenient
          Color Health wants to make cancer screenings convenient

          AColorHealthservicepromisestomakeiteasiertogetcancerscreenings.ColorHealthColorHealthwantstotakeaway

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          Medicare Advantage proposed rates disappoint insurers

          AdobeYou’rereadingthewebversionofHealthCareInc., STAT’sweeklynewsletter followingtheflowofmoneyinmed